Founded in 2016, this R&D-driven company develops innovative and complex Rx generics via NCE and 505(b)(2) pathways in oncology, metabolic, and CNS therapy areas. Specializes in peptide and LNP-based injectable and oral formulations targeting global regulated markets. Pursues US FDA and EU approvals through strategic development and licensing partnerships.